You are here: Home » Companies » News
Business Standard

Zydus Cadila gets USFDA nod for cancer, high blood pressure treatment drug

Drug firm Zydus Cadila on Thursday said it has received final approval from the US health regulator to market Ibrutinib Capsules, used to treat certain cancers

Topics
Zydus Cadila | Zydus Pharmaceuticals | Zyudus Wellness

Press Trust of India  |  New Delhi 

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing

Drug firm on Thursday said it has received final approval from the US health regulator to market Ibrutinib Capsules, used to treat certain cancers.

The company has also received nod to market Macitentan tablets, used to treat high blood pressure, in the American market.

has received final approval from the US Food and Drug Administration (USFDA) to market Ibrutinib Capsules in the strengths of 70 mg and 140 mg, Cadila Healthcare said in a regulatory filing.

Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.

The company said is eligible for 180 days of generic drug exclusivity for Ibrutinib Capsules, 70 mg and for Ibrutinib Capsules, 140 mg.

The 70 mg capsule has brand sales of USD 32.5 million, while the 140 mg dose has brand sales of USD 745.9 million, the company added.

Zydus Group Managing Director Sharvil Patel said the company has been investing significantly in building a portfolio of complex generic products and leveraging capabilities that will help it successfully commercialise and gain meaningful market share in the complex generic products and difficult-to-manufacture generic products.

"We have created a diversified portfolio of over 50 filed complex abbreviated new drug applications (ANDAs) seeking USFDA approval and we will continue to expand this as we explore opportunities to grow our US business in 2021 and beyond, he said.

In a separate filing, said it has received final approval from the USFDA to market Macitentan tablets, 10 mg.

According to the USFDA letter, Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Macitentan Tablets, 10 mg. Therefore, with this approval, Zydus is eligible for 180 days of shared generic drug exclusivity for Macitentan Tablets, 10 mg.

The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, April 08 2021. 11:20 IST
RECOMMENDED FOR YOU
.